Patents by Inventor Jeffrey A. Sterling
Jeffrey A. Sterling has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20070100001Abstract: The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.Type: ApplicationFiled: November 10, 2006Publication date: May 3, 2007Inventors: Moussa Youdim, John Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Izila Yeilin, Alexander Veinberg
-
Publication number: 20070021450Abstract: Disclosed are compounds having the structure: wherein, R1 is H, NH2, NH—(C1-C4)alkyl, or N—[(C1-C4)alkyl]2; R2 and R3 are each independently H, (C1-C4)alkyl, or wherein R4 is H, (C1-C4)alkyl, halogen, hydroxy, (C1-C10)alkoxy, cyano, nitro, —NR5R6, or —OCONR7R8; wherein R5 and R6 are each independently H, or a substituted or unsubstituted (C1-C4)alkyl; and wherein R7 and R8 are each independently H, or substituted or unsubstituted (C1-C4)alkyl, or (C1-C10)aryl; and wherein only one of R2 and R3 is H, enantiomers, tautomers, and pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic and inflammatory disorders, methods of preventing oxidation of lipids, proteins, or deoxyribonucleic acids on a cellular level, and methods of protecting human red blood cells from lysis by O2 radicals.Type: ApplicationFiled: July 15, 2005Publication date: January 25, 2007Inventors: Benjamin Sklarz, Eliezer Falb, Gyorgy Toth, Yaacov Herzig, Jeffrey Sterling
-
Publication number: 20060173053Abstract: Basic esters of fatty alcohols of the general formula: R1-O—CO-A or pharmaceutically acceptable salts thereof, wherein R1 is C12-C24 alkyl or C10-C24 alkenyl, and A is a residue containing at least one acyclic or cyclic amino group and/or at least one heteroaromatic ring containing a tertiary or quaternary nitrogen atom, are anti-inflammatory and immunomodulatory agents, useful in the treatment of immunologically-mediated inflammation, as adjuvants for antigens involved in both cellular and humoral responses.Type: ApplicationFiled: December 19, 2005Publication date: August 3, 2006Inventors: Meir Shinitzky, Irun Cohen, Raanan Margalit, Yaacov Herzig, Jeffrey Sterling, Gyorgy Toth, Istvan Miskolczi, Ferenc Rantal, Tivadar Tamas
-
Publication number: 20060094783Abstract: The subject invention provides methods of treating a subject afflicted with Parkinson's disease, memory disorder, depression, hyperactive syndrome, Attention Deficit Disorder, dementia, brain ischemia, stroke, head trauma injury, spinal trauma injury, neurotrauma, neurodegenerative disease, neurotoxic injury, multiple sclerosis, nerve damage, affective illness, schizophrenia or symptoms of withdrawal from an addictive substance, using the mesylate salt of R(+)-N-propargyl-1-aminoindan.Type: ApplicationFiled: June 17, 2005Publication date: May 4, 2006Inventors: Moussa Youdim, John Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Tzila Yellin, Alex Veinberg, Veinberg Alexander
-
Publication number: 20060025446Abstract: Disclosed are compounds having the structure: wherein Z is —OH or —O•; and A is: wherein X and Y are independently NR1 or O, where R1 is H or C1-C4 alkyl; and R2 is H, C1-C4 alkyl or t-butoxycarbonyl, wherein W is C3-C4 alkynyl; and R1 is H or C1-C4 alkyl, or wherein R1 is H, C1-C4 alkyl, or C3-C4 alkynyl; and R3 is H, OH, O(C1-C4 alkyl), or a halogen, optically active enantiomers, pharmaceutically acceptable salts of the compounds, pharmaceutical compositions containing such compounds or salts, and processes for their preparation. The subject invention also provides methods of alleviating symptoms of neurologic, autoimmune, and inflammatory disorders caused by the presence of reactive oxygen species, methods of preventing oxidation of lipids, proteins, or deoxyribonucleic acids on a cellular level, and methods of protecting human red blood cells from lysis by O2 radicals.Type: ApplicationFiled: July 26, 2005Publication date: February 2, 2006Inventors: Jeffrey Sterling, Benjamin Sklarz, Yaacov Herzig, David Lerner, Eliezer Falb, Haim Ovadia
-
Patent number: 6956060Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: GrantFiled: November 27, 2002Date of Patent: October 18, 2005Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Publication number: 20050197365Abstract: The subject invention provides a compound having the structure: wherein Y is O, NR3R4 or NOR6; R3 is H, alkyl, aralkyl, alkynyl, trifluoroacetyl, t-butoxycarbonyl or an acyl group; R4 is H, alkyl, aralkyl, or alkynyl; R6 is H or C1-C4 alkyl; R1 and R2 are each independently H, alkyl, aralkyl, or alkynyl; the curved line drawn from S to the center of the phenyl ring and the straight line drawn from N to the center of the ring indicate that S and N are part of a 5 membered ring which shares two carbons with the phenyl ring; and the dashed line drawn from the carbon atom on the cyclopentyl ring to Y represents a bond when Y is O or NOR6 and is absent when Y is NR3R4, and wherein wherein X is H or O; and R5 is H, alkyl, trifluoroacetyl, t-butoxycarbonyl or an acyl group, or an enantiomer, or a tautomer, or a pharmaceutically acceptable salt thereof, a process for preparing the compounds and a method of treating Parknison's disease, multiple sclerosis or depression with the compounds of the invention.Type: ApplicationFiled: February 25, 2005Publication date: September 8, 2005Inventors: Jeffrey Sterling, Liat Hayardeny-Nisimov, David Lerner, Yaacov Herzig, Eliezer Falb, Gyorgy Toth, Sandor Molnar, Dalia Pinkert
-
Publication number: 20040176430Abstract: The subject invention provides compounds having the structure: 1Type: ApplicationFiled: November 20, 2003Publication date: September 9, 2004Inventors: Jeffrey Sterling, Liat Hayardeny, Eliezer Falb, Yaacov Herzig, David Lerner
-
Publication number: 20040010038Abstract: The subject invention provides derivatives of propargylamino indan (PAI) and propargylamino tetralin that selectively inhibit monoamine oxidase (MAO) in the brain, having the structure: 1Type: ApplicationFiled: February 27, 2003Publication date: January 15, 2004Inventors: Eran Blaugrund, Yaacov Herzig, Jeffrey Sterling
-
Publication number: 20030212145Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an effective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: ApplicationFiled: November 27, 2002Publication date: November 13, 2003Applicants: Teva Pharmaceutical Industries, Ltd., Technion Research Development Foundation, Ltd.Inventors: Moussa B.H. Youdim, John P.M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Patent number: 6630514Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan, or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.Type: GrantFiled: October 26, 2001Date of Patent: October 7, 2003Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling
-
Publication number: 20030065038Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargy-1-aminoindan, or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.Type: ApplicationFiled: October 26, 2001Publication date: April 3, 2003Applicant: Teva Pharmaceutical Industries, Ltd.Inventors: Moussa B.H. Youdim, John P.M. Finberg, Ruth Levy, Jeffrey Sterling
-
Patent number: 6538025Abstract: This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: August 31, 2001Date of Patent: March 25, 2003Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd., Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B.H. Youdim
-
Publication number: 20020188020Abstract: This invention is directed to compounds of the following formula: 1Type: ApplicationFiled: August 31, 2001Publication date: December 12, 2002Applicant: Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B.H. Youdim
-
Patent number: 6462222Abstract: This invention is directed to compounds of the following formula: wherein when a is 0, b is 1 or 2; when a is 1, b is 1, m is from 0-3, X is 0 or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R1 and R4 are each independently hydrogen, C1-6 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome. Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: August 31, 2001Date of Patent: October 8, 2002Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation, Ltd.Inventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B. H. Youdim
-
Patent number: 6316504Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing the same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject.Type: GrantFiled: November 16, 1998Date of Patent: November 13, 2001Assignees: Technion Research and Development Foundation, Ltd., Teva Pharmaceuticals Industries, Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg
-
Patent number: 6303650Abstract: This invention is directed to compounds of the following formula wherein when a is O, b is 1 or 2; when a is 1, b is 1, m is from 0-3 X is O or S, Y is halogeno, R1 is hydrogen C1-4 alkyl, R2 is hydrogen, C1-4 alkyl, or optionally substituted propargyl and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 aralkyl each optionally substituted. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADC), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: June 18, 1999Date of Patent: October 16, 2001Assignees: Yissum Research Development Company of the Hebrew University of Jerusalem, Technion Research and Development Foundation, Ltd., Teva Pharmaceutical Industries, Ltd.Inventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B. H. Youdim
-
Patent number: 6251938Abstract: This invention is directed to compounds of the following formula: wherein m is from 0-4; X is O or S; Y is halogeno; R1 is hydrogen or C1-4 alkyl; R2 is hydrogen, C1-4 alkyl or optionally substituted propargyl; and R3 and R4 are each independently hydrogen, C1-8 alkyl, C6-12 aryl, C6-12 cycloalkyl or C6-12 aralkyl, R5 is hydrogen or C1-4 alkyl; and pharmaceutically acceptable salts thereof, provided that when X is O, R2 is optionally substituted propargyl. This invention is also directed to the use of these compounds for treating depression, Attention Deficit Disorder (ADD), Attention Deficit and Hyperactivity Disorder (ADHD), Tourette's Syndrome, Alzheimer's Disease and other dementia's such as senile dementia, dementia of the Parkinson's type, vascular dementia and Lewy body dementia. This invention is further directed to a pharmaceutical composition comprising a therapeutically effective amount of the above-defined compounds and a pharmaceutically acceptable carrier.Type: GrantFiled: June 18, 1999Date of Patent: June 26, 2001Assignees: Teva Pharmaceutical Industries, Ltd.,, Technion Research and Development Foundation, Ltd.,, Yissum Research Development Company of the Hebrew University of JerusalemInventors: Michael Chorev, Tamar Goren, Yacov Herzig, Jeffrey Sterling, Marta Weinstock-Rosin, Moussa B. H. Youdim
-
Patent number: 5786390Abstract: The subject invention relates to pharmaceutical composition of R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof.Type: GrantFiled: June 6, 1995Date of Patent: July 28, 1998Assignees: Teva Pharmaceutical Industries Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Tirtsah Berger-Paskin, Haim Yellin, Alex Veinberg
-
Patent number: 5744500Abstract: The subject invention provides R(+)-N-propargyl-1-aminoindan and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions containing same. The subject invention also provides methods of treating a subject afflicted with Parkinson's disease, a memory disorder, dementia, depression, hyperactive syndrome, an affective illness, a neurodegenerative disease, a neurotoxic injury, stroke, brain ischemia, a head trauma injury, a spinal trauma injury, neurotrauma, schizophrenia, an attention deficit disorder, multiple sclerosis, or withdrawal symptoms, using R(+)-N-propargyl-1-aminoindan or the pharmaceutically acceptable salt of the subject invention. The subject invention further provides a method of preventing nerve damage in a subject. Finally, the subject invention provides methods of preparing R(+)-N-propargyl-1-aminoindan, a salt thereof, and racemic N-propargyl-1-aminoindan.Type: GrantFiled: May 22, 1995Date of Patent: April 28, 1998Assignees: Teva Pharmaceutical Industries, Ltd., Technion Research and Development Foundation Ltd.Inventors: Moussa B. H. Youdim, John P. M. Finberg, Ruth Levy, Jeffrey Sterling, David Lerner, Haim Yellin, Alex Veinberg